Lineage Cell Therapeutics
LCTX
115 hedge funds and large institutions have $82.5M invested in Lineage Cell Therapeutics in 2023 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 27 increasing their positions, 25 reducing their positions, and 4 closing their positions.
1,400% more call options, than puts
Call options by funds: $15K | Put options by funds: $1K
275% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 4
11% more funds holding
Funds holding: 104 → 115 (+11)
8% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 25
0.12% more ownership
Funds ownership: 43.15% → 43.26% (+0.12%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
7% less capital invested
Capital invested by funds: $89.1M → $82.5M (-$6.58M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Raffles Associates
New York
|
+$596K |
| 2 |
Morgan Stanley
New York
|
+$219K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$209K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$185K |
| 5 |
Barclays
London,
United Kingdom
|
+$174K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$829K |
| 2 |
LCM
Laurion Capital Management
New York
|
-$770K |
| 3 |
DC
Defender Capital
Charlotte,
North Carolina
|
-$235K |
| 4 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$165K |
| 5 |
Citigroup
New York
|
-$120K |
LCTX Hedge Fund Activity: Q4 2023 in Review
115 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q4 2023, worth a combined $82.5M — down 7.4% from $89.1M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new LCTX positions and 4 closed out — a net gain of 11 holders — while 27 added to existing stakes and 25 trimmed.
The largest buyer was Raffles Associates, adding an estimated $596K. The largest seller was BlackRock, cutting an estimated $829K.
- 115 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q4 2023, up from 104 in Q3 2023.
- Funds reported $82.5M of Lineage Cell Therapeutics stock for Q4 2023, down 7.4% quarter-over-quarter.
- 15 funds opened new Lineage Cell Therapeutics positions in Q4 2023 and 4 closed out, a net change of +11 holders.
- The largest Lineage Cell Therapeutics buyer in Q4 2023 was Raffles Associates, an estimated $596K added.
- The largest Lineage Cell Therapeutics seller in Q4 2023 was BlackRock, an estimated $829K sold.
Based on aggregated 13F filings for Q4 2023.